Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

Rami S. Komrokji; Uwe Platzbecker; Pierre Fenaux; Amer M. Zeidan; Guillermo Garcia-Manero; Ghulam J. Mufti; Valeria Santini; María Díez-Campelo; Carlo Finelli; Joseph G. Jurcic; Peter L. Greenberg; Mikkael A. Sekeres; Amy E. DeZern; Michael R. Savona; Jeevan K. Shetty; Rodrigo Ito; George Zhang; Xianwei Ha; Jay T. Backstrom; Amit Verma

doi:10.1038/s41375-022-01521-4

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

Rami S. Komrokji, Uwe Platzbecker, Pierre Fenaux, Amer M. Zeidan, Guillermo Garcia-Manero, Ghulam J. Mufti, Valeria Santini, María Díez-Campelo, Carlo Finelli, Joseph G. Jurcic, Peter L. Greenberg, Mikkael A. Sekeres, Amy E. DeZern, Michael R. Savona, Jeevan K. Shetty, Rodrigo Ito, George Zhang, Xianwei Ha, Jay T. Backstrom, Amit Verma

Oncology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	1432-1435
Number of pages	4
Journal	Leukemia
Volume	36
Issue number	5
DOIs	https://doi.org/10.1038/s41375-022-01521-4
State	Published - May 2022

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41375-022-01521-4

Cite this

Komrokji, R. S., Platzbecker, U., Fenaux, P., Zeidan, A. M., Garcia-Manero, G., Mufti, G. J., Santini, V., Díez-Campelo, M., Finelli, C., Jurcic, J. G., Greenberg, P. L., Sekeres, M. A., DeZern, A. E., Savona, M. R., Shetty, J. K., Ito, R., Zhang, G., Ha, X., Backstrom, J. T., & Verma, A. (2022). Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia, 36(5), 1432-1435. https://doi.org/10.1038/s41375-022-01521-4

Komrokji, RS, Platzbecker, U, Fenaux, P, Zeidan, AM, Garcia-Manero, G, Mufti, GJ, Santini, V, Díez-Campelo, M, Finelli, C, Jurcic, JG, Greenberg, PL, Sekeres, MA, DeZern, AE, Savona, MR, Shetty, JK, Ito, R, Zhang, G, Ha, X, Backstrom, JT & Verma, A 2022, 'Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis', Leukemia, vol. 36, no. 5, pp. 1432-1435. https://doi.org/10.1038/s41375-022-01521-4

@article{7f59fee5fff948d8a5db9676ae7c8f05,

title = "Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis",

author = "Komrokji, {Rami S.} and Uwe Platzbecker and Pierre Fenaux and Zeidan, {Amer M.} and Guillermo Garcia-Manero and Mufti, {Ghulam J.} and Valeria Santini and Mar{\'i}a D{\'i}ez-Campelo and Carlo Finelli and Jurcic, {Joseph G.} and Greenberg, {Peter L.} and Sekeres, {Mikkael A.} and DeZern, {Amy E.} and Savona, {Michael R.} and Shetty, {Jeevan K.} and Rodrigo Ito and George Zhang and Xianwei Ha and Backstrom, {Jay T.} and Amit Verma",

note = "Funding Information: The study was supported by Celgene, a Bristol-Myers Squibb Company, in collaboration with Acceleron Pharma. Writing and editorial assistance were provided by James Matthews, PhD, of Excerpta Medica, funded by Bristol Myers Squibb. Funding Information: RSK: Advisory board fees from AbbVie, Acceleron, BMS, Geron, Jazz Pharmaceuticals, and Novartis; speakers{\textquoteright} bureau fees from BMS and Jazz Pharmaceuticals. UP: Grant support from Amgen, Janssen Biotech, Merck and Novartis; grant and travel support, and lecture, steering committee, and consulting fees, travel support from Celgene/BMS; and lecture fees from Novartis. PF: Consulting fees from Celgene. AMZ: Grant support, honoraria, clinical trial committee and consulting fees, from AbbVie, Celgene/BMS, and Novartis; consulting fees and honoraria from Acceleron, Agios, Astellas. Beyondspring, Cardinal Health, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Seattle Genetics, Syndax, Taiho, and Tyme; grant support from ADC Therapeutics, Astex and Medimmune/ AstraZeneca; grant support, consulting fees and honoraria from Amgen, Aprea, Boehringer-Ingelheim, Cardiff Oncology, Incyte, Otsuka, Pfizer, Takeda, and Trovagene; honoraria, consulting and clinical trial committee fees from Gilead and Kura; clinical trial committee fees from Geron. GG-M: Grant support and consulting fees from Astex Pharmaceuticals, BMS, Genentech, and Helsinn Healthcare; grant support from AbbVie, Amphivena Therapeutics, Aprea, Curis, Celgene, Forty Seven, H3 Biomedicine, Janssen, Merck, Novartis, and Onconova Therapeutics. GJM: Grant support from Celgene/BMS and Novartis. VS: Advisory board and lecture fees from Celgene/BMS; travel support from Janssen Biotech; advisory board fees from Geron, Gilead, Menarini, Novartis, and Takeda Oncology; grant support from Celgene. MD-C: Consulting fees from Celgene/BMS, Novartis, and Takeda. CF: Grant support, advisory committees, and speaker fees from Celgene/BMS; advisory committee and speaker fees from Novartis; consultancy from Takeda; advisory board fees from Janssen Pharmaceuticals. JGJ: Grant and travel support, and advisory board fees, AbbVie; grant support from Arog Pharmaceuticals, Astellas Pharma, Forma Therapeutics, Genentech USA, Gilead Sciences, PTC Therapeutics, and Syros Pharmaceuticals; advisory board fees from AstraZeneca; grant support, advisory board fees, and travel support from BMS/Celgene; grant support and consulting fees from Daiichi Sankyo; end-point committee fees from Novartis. PLG: Grant support from Celgene. MAS: Advisory boards for BMS, Gilead, Novartis, and Pfizer. AED: No competing financial interests. MRS: Steering committee and data and safety monitoring board fees from Celgene; consultancy and advisory for CTI, Geron, Karyopharm, Novartis, Ryvu, Taiho, Takeda, and TG Therapeutics; grant support from Astex, Incyte, Takeda, and TG Therapeutics; and equity in Karyopharm. JKS: Current employment at and equity in BMS. RI: Former employment and current equity in BMS; current employment and equity in Eli Lilly and Company. GZ and XH: Current employment at BMS. JTB: equity in BMS; current employment and equity in Acceleron Pharma. AV: Equity in Stelexis; consultancy and grant support from BMS; consultancy and honoraria from Acceleron Pharma; grant support from Janssen and Medpacto. ",

year = "2022",

month = may,

doi = "10.1038/s41375-022-01521-4",

language = "English (US)",

volume = "36",

pages = "1432--1435",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

AU - Komrokji, Rami S.

AU - Platzbecker, Uwe

AU - Fenaux, Pierre

AU - Zeidan, Amer M.

AU - Garcia-Manero, Guillermo

AU - Mufti, Ghulam J.

AU - Santini, Valeria

AU - Díez-Campelo, María

AU - Finelli, Carlo

AU - Jurcic, Joseph G.

AU - Greenberg, Peter L.

AU - Sekeres, Mikkael A.

AU - DeZern, Amy E.

AU - Savona, Michael R.

AU - Shetty, Jeevan K.

AU - Ito, Rodrigo

AU - Zhang, George

AU - Ha, Xianwei

AU - Backstrom, Jay T.

AU - Verma, Amit

N1 - Funding Information: The study was supported by Celgene, a Bristol-Myers Squibb Company, in collaboration with Acceleron Pharma. Writing and editorial assistance were provided by James Matthews, PhD, of Excerpta Medica, funded by Bristol Myers Squibb. Funding Information: RSK: Advisory board fees from AbbVie, Acceleron, BMS, Geron, Jazz Pharmaceuticals, and Novartis; speakers’ bureau fees from BMS and Jazz Pharmaceuticals. UP: Grant support from Amgen, Janssen Biotech, Merck and Novartis; grant and travel support, and lecture, steering committee, and consulting fees, travel support from Celgene/BMS; and lecture fees from Novartis. PF: Consulting fees from Celgene. AMZ: Grant support, honoraria, clinical trial committee and consulting fees, from AbbVie, Celgene/BMS, and Novartis; consulting fees and honoraria from Acceleron, Agios, Astellas. Beyondspring, Cardinal Health, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Seattle Genetics, Syndax, Taiho, and Tyme; grant support from ADC Therapeutics, Astex and Medimmune/ AstraZeneca; grant support, consulting fees and honoraria from Amgen, Aprea, Boehringer-Ingelheim, Cardiff Oncology, Incyte, Otsuka, Pfizer, Takeda, and Trovagene; honoraria, consulting and clinical trial committee fees from Gilead and Kura; clinical trial committee fees from Geron. GG-M: Grant support and consulting fees from Astex Pharmaceuticals, BMS, Genentech, and Helsinn Healthcare; grant support from AbbVie, Amphivena Therapeutics, Aprea, Curis, Celgene, Forty Seven, H3 Biomedicine, Janssen, Merck, Novartis, and Onconova Therapeutics. GJM: Grant support from Celgene/BMS and Novartis. VS: Advisory board and lecture fees from Celgene/BMS; travel support from Janssen Biotech; advisory board fees from Geron, Gilead, Menarini, Novartis, and Takeda Oncology; grant support from Celgene. MD-C: Consulting fees from Celgene/BMS, Novartis, and Takeda. CF: Grant support, advisory committees, and speaker fees from Celgene/BMS; advisory committee and speaker fees from Novartis; consultancy from Takeda; advisory board fees from Janssen Pharmaceuticals. JGJ: Grant and travel support, and advisory board fees, AbbVie; grant support from Arog Pharmaceuticals, Astellas Pharma, Forma Therapeutics, Genentech USA, Gilead Sciences, PTC Therapeutics, and Syros Pharmaceuticals; advisory board fees from AstraZeneca; grant support, advisory board fees, and travel support from BMS/Celgene; grant support and consulting fees from Daiichi Sankyo; end-point committee fees from Novartis. PLG: Grant support from Celgene. MAS: Advisory boards for BMS, Gilead, Novartis, and Pfizer. AED: No competing financial interests. MRS: Steering committee and data and safety monitoring board fees from Celgene; consultancy and advisory for CTI, Geron, Karyopharm, Novartis, Ryvu, Taiho, Takeda, and TG Therapeutics; grant support from Astex, Incyte, Takeda, and TG Therapeutics; and equity in Karyopharm. JKS: Current employment at and equity in BMS. RI: Former employment and current equity in BMS; current employment and equity in Eli Lilly and Company. GZ and XH: Current employment at BMS. JTB: equity in BMS; current employment and equity in Acceleron Pharma. AV: Equity in Stelexis; consultancy and grant support from BMS; consultancy and honoraria from Acceleron Pharma; grant support from Janssen and Medpacto.

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85125242726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125242726&partnerID=8YFLogxK

U2 - 10.1038/s41375-022-01521-4

DO - 10.1038/s41375-022-01521-4

M3 - Article

C2 - 35220402

AN - SCOPUS:85125242726

SN - 0887-6924

VL - 36

SP - 1432

EP - 1435

JO - Leukemia

JF - Leukemia

IS - 5

ER -

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this